Recent BioUtah News & Events

A new report from the U.’s Kem C. Gardner Policy Institute uncovers the wide-ranging mechanisms driving Utah’s high performance when it comes to innovation output

Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics. The program, launching this month, will run for a minimum of three years.

Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model

Human Forms and Body Parts Trigger Strong Reactions in the Brain

Partnership aims to set new industry standards for managing mental health and cognitive conditions

SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS

BD has reached an agreement with the U.S. SEC to resolve the previously disclosed investigation related to prior public disclosures.

VALENCIA, Calif. – Dec. 3, 2024 – Nusano, a physics company transforming the production of radioisotopes, today announced the creation of a Medical Radioisotopes Advisory Board. This panel of internationally recognized leaders in nuclear medicine will provide strategic guidance to Nusano, ensuring its product development aligns with emerging trends and with the needs of cancer […]

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.’s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India. In support of the “Make […]

LEHI, Utah, Dec. 10, 2024 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today promising topline data resulting in the advancement to the second stage of its Phase 2 clinical trial evaluating HT-6184, a first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor given orally, in patients with lower-risk […]

Recursion reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.

With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide hope for patients and doctors

BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance

Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company’s Comprehensive Patient-Centric Solutions

Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore®

Presentation to Highlight Feasibility and Interest in Decentralized Home-Based Phase 3 Trial Salt Lake City, Utah — December 5, 2024 — PhotoPharmics, a pioneer in non-invasive phototherapy for neurological disorders, today announced it will present a poster titled “An Entirely Remote, Home-based Phase 3 Clinical Trial of a Specialized Light Therapy Device for Parkinson’s Disease […]

November 27, 2024—Fluidx Medical Technology, Inc. announced that the first patient has been treated in the prospective, multinational, clinical trial of the company’s GPX embolic device. The device was successfully used in a portal vein embolization procedure in preparation for hepatic resection. According to the company, the safety and effectiveness trial includes leading medical centers […]

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor BIIB122 (DNL151) in participants with LRRK2-associated Parkinson’s disease (LRRK2-PD). LRRK2 inhibition is a potential therapeutic approach that […]

Canary Speech recognized for achievements in non-invasive diagnostics in the most promising private digital health companies across the globe.

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized

Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses.

EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA

WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial

More than a dozen Utah legislators on Wednesday, November 20, held a breakfast meeting of the Utah Life Sciences Innovation Caucus (ULSIC) at the state capitol.